Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. Sales growth was primarily volume-driven, though results also included “a couple of hundred millions” of positive gross-to-net adjustments. Beyfortus sales increased 54% to €108 million, while Efluelda sales rose 43% on a pro forma basis to €113 million. For full-year 2026, Sanofi expects vaccines sales to be slightly negative, with the impact concentrated in the second half. For 2030, Sanofi maintained its ambition for pharmaceutical launches to generate about €10 billion in sales and expects vaccines sales of about €9 billion.